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     3   ABBREVIATIONS 
 
 
     AJCC 
     CCRCC 
     CCTS 
     CDK 
    CSS 
     CT 
     EPO                       
     ESR 
     ECOG PS 
 
     HGF 
     HIF 
     HTN 
     HR 
     INFα 
     KPS 
     LND 
     LNI 
     MDM 
     MET 
     mRCC 
     MVI 
     MVD 
     NG 
     PDGF 
     PI 
     RCC 
     RN 
     SDM 
     TGF 
     TSC 
     TSP-1 
     TNM 
     VCI 
     VEGF 
     VHL 
     VI 
 
American Joint Committee on Cancer stage grouping  
Clear cell renal cell carcinoma       
Continuously coded tumor size 
Cyclin dependent kinase    
Cancer-specific survival 
Computer tomography 
Erythropoietin 
Erythrocyte sedimentation rate 
Eastern Cooperative Oncology Group Performance  
Status 
Hepatocyte growth factor  
Hypoxia-inducible factor 
Histological tissue necrosis                         
Hazard ratio  
Interferon alfa 
Karnofsky Performance Scale 
Lymph node dissection    
Lymph node invasion 
Metachronous distant metastases      
MET Oncogene 
Metastatic RCC        
Microvascular invasion            
Microvessel density          
Nuclear grade 
Platelet-derived growth factor  
Proliferation index 
Renal cell carcinoma 
Radical nephrectomy 
Synchronous distant metastases                                  
Transforming growth factor                                                  
Tumor suppressor gene                
Thrombospondin-1 
Tumor Node Metastasis 
Vena cava inferior  
Vascular endothelial growth factor 
von Hippel-Lindau tumor suppressor gene       
Venous invasion 
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4    GENERAL INTRODUCTION 
 
   
4.1    Epidemiology 
 
Approximately 3% of all malignant tumors in adults arise in the kidney. Renal cell 
carcinoma (RCC) is a heterogeneous group of sporadic or hereditary cancers that 
develop from kidney cells. Its frequency is next to prostate and bladder cancer, but it 
is the most lethal of these malignancies. The incidence of RCC has been reported to 
be relatively high in North America, Scandinavia and Australia compared to other 
countries.1 The incidence is steadily increasing at a rate of 2-3% per year.2-3 In the 
Swedish County of Värmland age standardized incidence rates for RCC in the period 
1985 to 1994 were 6.7 (cases per person-year) for females and 9.9 for males, 
compared to 9.3 and 15.9, respectively for Sweden and 5.7 and 9.6, globally.4 It is 
estimated that approximately 20-30% of the patients present with metastatic 
disease.5-6 It is also well known that low T-stage tumors can occur with advanced 
overall TNM stage and in some studies they account for 25% of widely metastatic, 
stage IV disease.7  
 
4.2   Age, gender, and geographical distribution 
Most commonly RCC occurs in the fourth to sixth decades of life, but both sporadic 
and in particular hereditary tumors have been reported in children.  
RCC has male to female preponderance of 1.5:1.8-10 It is more common in 
Scandinavians and white North Americans than in those of Asian or African descent.   
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4.3    Etiology, pathogenesis and risk factors 
At least 5 hereditary syndromes associated with renal cell carcinoma are recognized: 
von Hippel-Lindau (VHL) syndrome, hereditary papillary renal carcinoma, Birt-Hogg-
Dube’ syndrome, hereditary leiomyomatosis and renal cell carcinoma syndrome and 
renal cell tumors associated with tuberous sclerosis.  Defects of either tumor 
suppressor genes (VHL, TSC) or oncogenes (MET) in families at high risk may result 
in tumor formation.  
The tissue of origin for clear cell renal cell carcinoma (CCRCC) is the renal proximal 
tubular epithelium. It occurs in both a sporadic (nonhereditary) and a hereditary form. 
Both are associated with structural alterations of the short arm of chromosome 3 
(Figures 1 and 2). About 70%-80% of sporadic CCRCC have inactivation of the VHL 
gene because of a combination of allelic deletion and mutation or 
hypermethylation.11-12  
    
     Figure 1. Clear cell RCC. Note deletion of 3p as the only karyotype change.                      Figure 2.  Chromosome  
     (WHO classification of  tumors. 2004)                                                                 3 (human) 
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Figure 3. Control of Hypoxia-inducible factor (HIF) by the product of the von Hippel-Lindau gene (pVHL). From D.J. George and 
W.G. Kaelin Jr. (855).  Copyright 2003 Massachusetts Medical Society.  
 
Inactivation of VHL gene in CCRCC leads to increased level of hypoxia-inducible 
factor 1 (HIF1), activating a number of genes involved in angiogenesis and 
overexpression of vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), transforming growth factor alfa (TGF), and erythropoietin (EPO) 
(Figure 3). In papillary RCC a number of the cases have mutation of the MET 
Oncogene. The gene codes for the MET protein, which is receptor for hepatocyte 
growth factor (HGF). This molecular mechanism corresponds to the tyrosine kinase 
model for carcinogenesis.  
 
A number of environmental factors have been studied as possible risk factors for 
RCC.3 13-14 Cigarette smoking doubles the risk of renal cell carcinoma and contributes 
to as many as one third of all cases.15 Obesity is known particularly in females to 
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have a linear relationship with increasing risk. However, data on the prognostic 
impact of overweight in RCC is still conflicting.16 Hypertension, tuberous sclerosis, 
acquired renal cystic disease and regular use of analgesics may be associated with 
increased incidence of RCC.17-18 
 
4.4   Clinical presentation 
According to the mode of detection RCCs are classified in two groups: symptomatic 
and incidental. The classic clinical triad of pain, hematuria and flank mass is less 
frequent than previously seen and is indicative of advanced disease. 
The typical tumor is characterized by lack of early warning signs and may remain 
clinically occult for most of its course. The majority of RCCs are now diagnosed 
incidentally during investigations of unrelated complaints and due to the increasing 
use of imaging procedures, such as ultrasonography, computed tomography (CT) 
and magnetic resonance imaging (MRI).19-20  The tumors are often small and of 
significantly lower stage and grade.21-22 23 RCC remains an unique and challenging 
tumor because of its paraneoplastic manifestations including hypercalcaemia, 
erythrocytosis, increased erythrocyte sedimentation rate, and non-metastatic hepatic 
dysfunction. Most common presentations are hematuria (40%), flank pain (40%), 
mass in the flank or in the abdomen (25%), weight loss (33%), fever (20%), 
hypertension (20%), night sweats, malaise and varicocele, usually left sided, due to 
obstruction of the testicular vein (2% of males). 
The contribution of erythrocyte sedimentation rate (ESR) in prediction of prognosis 
has been a matter of debate in several studies.24-26 However, in the recent studies of 
Kawai et al.27 and Magera et al.28 preoperative ESR has been identified as a 
significant independent prognostic factor in patients with localized CCRCC. ESR is 
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also found to be an independent prognostic factor in patients with metastatic RCC 
(mRCC) treated with or without cytoreductive radical nephrectomy (RN) 29.  
 
 
4.5    Performance status 
 
Performance status (PS) measured by Karnofsky Performance Scale (KPS) or 
Eastern Cooperative Oncology Group performance status (ECOG PS) has been 
recognized as an important predictor of cancer-specific survival (CSS) in RCC.29-32 
KPS ranges from 0-100% was the most widely used assessment tool of performance 
status in oncology. Oken et al.1982 introduced a new simplified measuring system 
ECOG PS in 1982.33 However, the usefulness of ECOG PS in prognostication of 
RCC has been controversial in a number of studies.34-36  Even though ECOG PS and 
symptoms at presentation were of independent prognostic significance, the 
combination of those two variables in prognostic models did not improve the 
capability to predict RCC specific mortality.35   
 
Table 1 
 
Eastern Coopertive Group Performance Status (ECOG PS) 
 
 Grade Description  
----------------------------------------------------------------------------------------------------------------------------- - 
                                                                                                                              
 
0                 Fully active, able to carry on all pre-disease performance without restriction. 
 
1                Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature (such as light house work, office work).  
  
2                 Ambulatory and capable of all self-care, but unable to perform any 
                            work activities. Up and about more than 50% of waking hours.     
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3                 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
                            hours. 
 
4                  Completely disabled. Cannot carry on any self-care.  
                             Totally confined to bed or chair. 
 
5                    Deceased.------------------------------------------------------------------------------------------ 
     Adapted from Oken et al. (1982) 
 
 
 
4.6   Histopathology and tumor staging 
4.6.1   Histological subtypes 
The histological subtypes are diagnosed according to the Heidelberg classification 
guidelines (Table 2). The clear cell subtype (Figure 4) is the most common variant of 
RCC accounting for about 80% of this kind of tumor.37  The two other common RCC 
histological subtypes are papillary (Figure 5) and chromophobe (Figure 6) 
carcinomas. The prognostic impact of the histological subtype has been questioned 
in a number of reports.8 38-39 
Some studies have shown that CCRCC has the worst prognosis compared to 
papillary and chromophobe, which has the best prognosis. This concerns especially 
organ-localized tumors. When stage and nuclear grade were included in the analyses 
tumor type lost independent prognostic significance.10 40 However, the multilocular 
cystic variant of CCRCC and mucinous tubular and spindle cell RCC have favorable 
prognosis. Collecting duct and medullary carcinoma have poor prognosis. For all the 
major subtypes sarcomatoid dedifferentiation is associated with adverse prognosis. 
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Table 2 
The Heidelberg classification of renal cell tumors  
_____________________________________________________________________ 
 
       Malignant tumors 
  
 
      1. Clear cell renal cell carcinoma 
      2. Papillary renal cell carcinoma   
      3. Chromophobe renal carcinoma                                                                                            
4. Collecting duct carcinoma 
5. Medullary carcinoma 
6. Renal cell carcinoma, unclassified 
_____________________________________________________________________ 
 
                                                            
          
Figure  4.                                               Figure  5.                                                Figure  6. 
      Clear cell renal cell carcinoma       Papillary renal cell carcinoma       Chromophobe renal cell       
                                                                                                                   carcinoma 
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4.6.2   Nuclear grade 
For CCRCC the Fuhrman nuclear grading system (Table 4) has become widely 
used.41 Its intra- and interobserver reproducibility, however, has turned out to be 
rather low.42-44 Both how to grade and how many grades are of importance remain 
matters of debate.42 45 
 
Table 3 
 
Nuclear grading according Fuhrman 
________________________________________________ 
 
Grade 1: Nuclei are round, uniform, approximately 10µm with inconspicuous or absent nucleoli. 
 
Grade 2  Nuclei are slightly irregular, approximately 15 µm  with evident nucleoli.  
 
Grade 3 The nuclei are approximately 20 µm in size and may be oval in shape with large and    
                 prominent nucleoli. 
 
Grade 4  Nuclei are pleomorphic and  multilobated with large prominent nucleoli. 
________________________________________________ 
 
4.6.3   Tumor stage 
Flock and Kadesky introduced the first staging system for RCC in 1958.46 Robson et 
al.47 modified the system in 1967. Currently the most extensively used and generally 
recommended is the 2002 UICC TNM classification system (Table 3).48-49 it takes into 
account tumor size, extent of local disease and presence of metastases when 
grouping patients for both prognosis and selection of treatment. However, it is still 
uncertain whether this version of the classification is optimal for prognostication of 
survival for patients with RCC. It might be changed in the future.  
For many years tumors with the largest diameter less than 3cm were regarded as 
benign tumors/adenomas. However, in the last few years a new consensus suggests 
that all clear cell tumors should be considered carcinomas irrespective of size. It 
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remains controversial where the cut-off point lies between the different subgroups in 
the present TNM classification system.  
 
 
Table 4 
 
2002 TNM classification and stage grouping for renal cell carcinoma 
_____________________________________________________________________________ 
 
T       Primary tumor 
 
Tax     Primary tumor cannot be assessed 
 
T0     No evidence of primary tumor 
 
T1a   Tumor 4.0 cm or less in greatest dimension, limited to the kidney 
 
T1b   Tumor more than 4.0 but 7.0 cm or less in greatest dimension,  
 
         limited to the kidney 
 
T2     Tumor more than 7.0 cm in greatest dimension, limited to the  
 
          kidney  
 
T3a    Tumor invades adrenal gland or perinephric tissue but not  
 
          beyond Gerota fascia 
 
T3b    Tumor grossly extends into renal vein or vena cava below  
 
          diaphragm 
 
T3c    Tumor grossly extends into vena cava above diaphragm 
 
T4      Tumor invades beyond Gerota’s fascia 
 
 
 
N        Regional lymph nodes 
 
Nx      Regional lymph nodes cannot be assessed 
 
N0      No regional lymph node metastases 
 
N1      Metastasis in a single regional lymph node 
 
N2      Metastasis in more than one regional lymph node 
 
 
 
M         Distant metastasis 
 
Mx       Distant metastasis cannot be assessed 
 
M0       No distant metastasis 
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M1       Distant metastasis 
 
________________________________________________________________________ 
 
Stage groupings                               T                    N                       M 
________________________________________________________________________ 
 
I                                                           T1                  N0                     M0 
 
 
II                                                          T2                  N0                     M0 
 
 
III                                                          T1                  N1                    M0 
                                                             T2                  N1                    M0 
                                                             T3                  N0, N1              M0    
 
 
IV                                                          T4                  N0, N1              M0 
                                                              Any T            N2                     M0 
                                                              Any T            Any N                M1      
 
 
 
4.6.4   Tumor size 
In patients with organ-confined disease, tumor size is related to differences in 
survival rates. However, the prognostic cut-off points in the TNM staging system for 
different stages have been subject of different reports and controversies.32 38 50-51 A 
number of studies have suggested different cut-offs for the optimal T1 size for 
patients undergoing surgical resection for organ confined RCC. Nevertheless, all 
these studies confirm that primary tumor size is an important factor for prognosis.5 
Most reports suggest that the optimal cut-off size for predicting outcome is between 4 
and 10 cm.52 53-54  Lau et al. in their study suggested a cut-off point of 5 cm for 
pathologic stage T1 patients.53 Frank et al. proposed that pathologic stage T2 (pT2) 
should be subdivided in pT2a (>7but<10cm) and pT2b (>10cm) in order to improve 
the prognostic accuracy of the 2002 TNM classification.52 Furthermore, the 
continuously coded tumor size was reported to be more informative and to improve 
the predictive accuracy as compared to the categorized pT stage.55-56   
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4.6.5   Venous involvement, lymph node invasion and metastases 
Stage T3 tumors are currently divided into those without vein involvement (T3a) and 
those with vein involvement below the diaphragm (T3b) or above the diaphragm 
(T3c). According to two recent studies, the presence but not the extent of venous 
invasion independently correlated with cancer-specific survival.57-58  
About 25% of patients with RCC present with metastatic disease, either lymph node 
infiltration or simultaneous distant metastases or both.50  
In general, distant metastases at operation have a profound adverse impact on 
survival after radical nephrectomy for RCC. The patients with lung or bony 
metastases have a worse prognosis than those with metastases limited to other 
organs. The lung is the most prevalent site of metastases when the tumor invades 
the renal vein or the vena cava.  
One of the most important prognostic factors in RCC is lymph node invasion (LNI). 
However, the prognostic discrimination between pN1 and pN2 categories in the 2002 
TNM system has been questioned. A recent study concludes that the percentage of 
positive nodes and a threshold number of four rather than one positive lymph node 
correlated significantly with clinical outcomes.59  
The appropriateness of the pNx/pN0 grouping and the prognostic relevance in a 
multivariate setting has also been discussed.60  The importance of extensive 
lymphadenectomy as a part of RN of RCC is still controversial after decades of 
evaluation.61-62    
The possible impact on CSS of interactions between LNI, synchronous distant 
metastases (SDM) and VI have not yet been fully studied. The importance of these 
interactions has been discussed in recent studies.63-64 
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4.7   Tumor biology 
4.7.1   Tumor biomarkers 
Progression in many tumors has been found to be associated with increased cell 
proliferaration, cell migration, angiogenesis and decreased programmed cell death 
(apoptosis). Inactivation of the VHL gene in CCRCC increases HIF1, which activates 
downstream genes involved in cell proliferation and neovascularization. In this 
respect, several putative biomarkers associated with cell-cycle progression (Figure 7) 
have been identified. 
 
 
Figure 7. The cell cycle ( The cell cycle & apoptosis, Sathiyaraj, 2007) 
 
The cyclin-dependent kinase (CDK) inhibitor p21  has been investigated as an 
important biomarker in RCC.65 The p21 protein is expressed in a number of tumors 
and normal tissues, but has specifically been associated with better clinical outcomes 
in patients having localized RCC. In metastatic disease, high levels of nuclear and 
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cytosolic p21 have been associated with reduced survival.65 In the modified RCC cell 
cycle, minichromosome maintenance 2 (Mcm2), Geminin and Ki-67 define the 
proliferative state.66 p27 is a member of the family of cyclin-dependent kinase 
inhibitors. It has been reported to be elevated in tumors compared with matched 
controls, and cytoplasmic mislocalization of p27 was associated with increasing 
tumor grade. 67 The loss of p21 expression is a risk factor for RCC progression. 68  
Inactivation of the p16 gene is a common mechanism for deregulation of cell cycle 
control in many tumors. Expression of the cyclin-dependent kinase 4 inhibitor A 
(p16INK4a) tumor suppressor protein is a positive prognosticator for cancer-specific 
survival in patients with RCC in both uni- and multivariate analyses.69   
  Ki-67, which is expressed in all phases of the cell cycle except G0 is a sensitive and 
specific marker of tumor cell proliferation. However, the value of this marker in 
prognostication of RCC remains controversial.70-72 Vascular cell adhesion molecule 1 
has also been implicated as a predictor of survival for mRCC.73 
p53 is a tumor suppressor gene and p53 mutations have been found in 20- 40% of 
CCRCC. The p53 protein is important for cellular responses involving cell cycle 
arrest, apoptosis and DNA repair. However, the role of p53 in RCC remains 
inconclusive. Some studies report that p53 overexpression is associated with 
sarcomatoid transformation and adverse prognosis while others could not find this 
association.  
The role of thrombospondins (TSPs) in angiogenesis and tumor progression in 
different human tumors has been a matter of controversy.74-77 TSPs are matricellular 
multifunctional glycoproteins secreted by most cell types and natural regulators of 
angiogenesis.78-79 Since tumors and their metastases are dependent on 
angiogenesis, which occurs almost exclusively in the microcirculation, the role of 
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angiogenesis in the growth and progression of cancer has received increasing 
attention. In an experimental study of TSP-1 and TSP-2, it was shown that co-
expression completely prevented tumor growth suggesting potential synergistic 
effects of these proteins. Inhibition of tumor growth by TSP-2 was not caused by 
direct inhibition of tumor cell proliferation.80 Nevertheless, there are discrepancies in 
published literature as to what extent and in what way TSP-1 influences tumor 
proliferation and angiogenesis. Izumi et al.81 reported that trastuzumab (Herceptin) is 
an antibody that inhibits cancer cell production of angiogenic factors such as TGF-β, 
angiopoietin-1, plasminogen activator inhibitor-1 and also up-regulates expression of 
the endogenous angiogenesis inhibitor, TSP-1. Rastinejad et al.82 demonstrated that 
a nontumorigenic hamster cell line generated a truncated form of TSP-1, a negative 
regulator of angiogenesis. These cells became tumorigenic in association with loss of 
suppressor gene, consecutive decrease of TSP-1 and switch to an angiogenic 
phenotype.  
Compelling evidence has emerged that p53 upregulates the expression of TSP-1 and 
that the loss of p53 function correlates with a reduction of TSP-1 protein expression 
and activation of angiogenic switch.79 83-85 As normal fibroblasts and mammary 
epithelial cells progress toward malignancy, they switch to an angiogenic phenotype. 
Wild-type p53 was shown to inhibit angiogenesis in these cells through regulation of 
TSP-1 synthesis.84 86 Inactivation of the p53 suppressor gene resulted in a dramatic 
reduction in the production of neovascularization inhibitors, while reintroduction of 
p53 stimulated secretion of TSP-1 and raised the antiangiogenic activity of the tumor 
cells.87  Similarly the absence of TSP-1 leads to an increase of vasculature and 
accelerated growth of mammary tumors that arise spontaneously in neu-transgenic 
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mice.87 TSP-1 blocks the ability of cultured capillary endothelial cells to organize into 
cords and to develop lumen formation.88 
 
 
4.7.2   Angiogenesis, microvessel density and histological tissue necrosis 
In their experimental studies of spontaneous tumors in transgenic murine models 
Hanahan et al.89-90 and Kandel et al.91  revealed that the angiogenic switch is a 
discrete event that develops in premalignant stages of tumorigenesis. However, most 
human tumors exist in situ for years then switch to an angiogenic phenotype. VEGF 
expression is inhibited by the VHL protein. In patients with VHL disease and in most 
sporadic clear cell carcinomas the VHL tumor suppressor gene is mutated which 
results in increased expression of VEGF. 92-93  
Microvessel density (MVD) measures the relative intensity of angiogenic activity in a 
majority of solid tumors and is correlated with metastasis and poorer prognosis.94 It 
has become a reproducible factor for the risk of metastases. MVD may not be useful 
to determine efficacy of antiangiogenic therapy in solid tumors, however, it continues 
to be a valid prognosticator of metastasis and survival.95-96  
Tumor necrosis has been found in 28-37% of CCRCC, most frequently in those with 
high nuclear grade. However, the prognostic importance of HTN is still a matter of 
debate.34 36 38-39 97-98 There is no consensus yet whether HTN should be included in 
the histopathology report and if it has to be quantified.     
 
4.7.3   Microvascular invasion 
The importance of microvascular invasion (MVI) for the prognosis of non-metastatic 
RCC has been discussed in only a few earlier reports, but with divergent 
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conclusions.99-105 There is also considerable variation in the reported frequencies of 
MVI. These discrepancies may be due to different staining methods, lack of 
standardized diagnostic criteria and interobserver variability. In two recent studies, 
however, MVI was found to be an independent prognosticator in patients with organ-
confined RCC treated with RN.106-107 Three other studies have concluded that MVI is 
an independent prognostic factor in all T-stages.108-110 However, MVI is not part of 
the 2002 TNM classification system and it is not regularly included in the 
histopathology report. 
 
4.8   Treatment of RCC 
4.8.1   Radical and partial nephrectomy   
Historically, the standard curative treatment for RCC has been RN.47 Management of 
RCC has advanced through the development of laparoscopic approaches and 
nephron-sparing surgery.111-112 Currently nephron-sparing surgery is the standard 
treatment for small renal tumors. Laparoscopic radical nephrectomy has been 
suggested as the new gold-standard113 and has to a large extent replaced the open 
approach which was the standard procedure between 1985 to 1994. 
 
4.8.2   Percutaneous cryoablation 
Small renal tumors are increasingly being discovered over the last decade due to 
increased use of abdominal imaging performed for other purposes. A population of 
small renal cortical tumors (median size 4.0 cm [T1]) has emerged, comprising 70% 
of the renal tumors that are incidentally detected.114 
 Due to decreased morbidity, preservation of the renal function, and shorter hospital 
stay, ablative techniques that destroy tumor tissue have gained interest in the last 
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decade.  Among the ablative modalities, cryoablation is the best documented 
procedure for treating small renal cortical tumors.115 This minimally invasive 
procedure is based on freezing the tumor tissue by using nitrogen or argon. MRI or 
CT scans are used subsequently in order to assess the ablation. If the treatment is 
found to be inadequate a percutaneous biopsy, a standard resection, or retreatment 
with cryoablation can be performed.  
 
 
 
4.8.3   Radiofrequency ablation  
Some patients with a small RCC are unable to undergo nephron-sparing surgery due 
to comorbidities. In older patients with a small incidentally discovered tumor growing 
at a slow rate, that does not represent an immediate threat to the patients’ life, 
watchful waiting and follow-up imaging could be appropriate.116-118  However, CT-
guided percutaneous radiofrequency ablation can be used to reliably eradicate small 
RCCs in patients who are unsuitable for surgery and desire a definitive treatment.111 
It can be performed in a day-hospital for selected patients.119  
 
4.8.4   Observation of renal masses  
According to a recent study120, non-treated smaller renal masses diagnosed in older 
and comorbid patients have a low growth rate of <1cm/yr in 85% of the cases, and 
100% 5-yr CSS.  These findings imply that this subgroup of patients with a high risk 
of postoperative morbidity and mortality could safely be selected for observation and 
not invasively treated.   
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4.8.5   Radiotherapy for metastases in RCC 
Historically, RCC is resistant to radiotherapy. However, this treatment option can be 
used for selected symptomatic patients with unresectable brain or osseous 
lesions.121-122 Combined radiotherapy and zoledronate in patients with bone 
metastases from RCC can induce a higher response rate than radiotherapy alone.123 
In individual cases whole brain irradiation, radio surgery and/or a stereotactic 
radiotherapy can induce symptom palliation and improve survival.124-126 
 
 
4.8.6   Targeted molecular therapies 
A defective copy of the VHL gene is the most common cause of inherited CCRCC. 
Furthermore, in most patients with sporadic CCRCC, the VHL gene is inactive. 
Hypoxia-inducible factor accumulation due to VHL inactivation, leads to production of 
several growth factors including VEGF, TGFα and PDGF, which promote neo-
angiogenesis and contributes to the development and progression of RCC. The 
PDGF and VEGF signalling pathways have been identified as targets for anticancer 
therapy. The targeting drugs, sorafenib, sunitinib, bevacizumab combined with INF-α 
(Figure 8), everolimus and temsirolimus have led to significant improvements in 
progression-free survival and have been approved for treatment of mRCC.127-128 129-
131 
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Figure 8.  Schematic representation of the main molecular events associated with 
                anticancer therapy by three targeting drugs: sorafenib, sunitinib and    
                bevacizumab. 
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5.  Aims of the thesis 
 
 
5.1   Paper I 
 
To examine the prognostic significance of performance status, tumor stage, 
histological subtype, nuclear grade and histological tumor necrosis (HTN) in a 
population of 196 consecutive patients subjected to radical nephrectomy for RCC.  
 
5.2   Paper II 
To evaluate the prognostic impact on CSS of microvascular invasion, nuclear 
grade, tumor size and pT-stage adjusted for age in CCRCC. A study was 
conducted on a complete cohort of 76 consecutive patients with pathologically organ-
confined CCRCC treated with radical nephrectomy.  
 
5.3    Paper III 
 
To investigate the possible prognostic significance of interactions between lymph 
node invasion, synchronous distant metastases, and venous invasion adjusted 
for mode of detection, Eastern Cooperative Oncology Group performance 
status, erythrocyte sedimentation rate and tumor size. This study investigated 
196 patients with renal cell carcinoma treated with radical nephrectomy. 
 
5.4. Paper IV 
To evaluate the possible associations between TSP-1, p53 expression, microvessel 
density, cell proliferation index, nuclear grade, tumor stage, and continuously 
coded tumor size. A study was conducted on 160 patients with CCRCC where the 
significance of TSP-1 as a prognostic marker in CCRCC was examined.  
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6. Patients and methods 
 
This chapter gives an overview of the patients included and the methods applied to 
fulfill the aims of the study. More specific details can be found in the corresponding 
papers. 
Approval to use the biological material for research purposes was granted in 2004 by 
the local authority at Karlstad Central Hospital in Sweden according to Swedish 
regulations. In Norway the appropriate Norwegian authority, Norwegian Social 
Science Data Services, acknowledged this approval. The study was carried out in 
accordance with the standards of the World Medical Association Declaration of 
Helsinki as revised in 2008.  
 
6.1     Patients and materials 
6.1.1   Paper I and III      
Between 1985 and 1994 a total of 203 consecutive patients underwent surgical 
treatment for RCC at five clinics in Värmland County, Sweden (average population 
282 570). Five patients who underwent partial nephrectomy and two who had 
oncocytoma were excluded. The study thus comprised 196 patients treated with 
standard radical nephrectomy. 
 
6.1.2   Paper II   
Of 196 patients a total of 52 with AJCC stage IV and 53 with AJCC stage III were 
excluded. After removing 12 patients with papillary and three with chromophobe 
carcinoma the study group consisted of 76 patients with organ-confined CCRCC.  
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6.1.3   Paper IV   
A total of 172 consecutive patients with CCRCC treated with radical nephrectomy 
during the years 1985 – 1994 were enrolled in the study. However, due to technical 
problems and lack of material, 12 cases without TSP-1 immunohistochemistry were 
excluded from the study. 
 
6.2     Data collection 
 Clinical records and pathology reports were reviewed to determine stage, size and 
type of the primary tumor. Clinical information regarding age, sex, symptoms, 
preoperative evaluation, treatment, local recurrences, metastases and final disease 
status were extracted retrospectively from the patients’ files.  
The biopsy material was examined at the Department of Pathology, Central Hospital, 
Karlstad, and at the Department of Pathology, Haukeland University Hospital, 
Bergen. In all cases studied, representative formalin fixed, paraffin embedded 
material was available for light microscopy and immunohistochemistry.  
The cause of death was determined from clinical records and death certificates. 
Deaths from causes other than RCC were censored. The Swedish Updated 
Population Register was searched. Concerning the surviving patients, local general 
practitioners were contacted in order to obtain the clinical status of these patients at 
30 April 2004, which represented the end of follow-up. Thus patients could be 
assigned a date of death or identified as being alive with or without diagnosed 
recurrent disease.  
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6.3     Data elaboration 
6.3.1   Tumor stage, nuclear grade and histological subtype 
Tumor staging was ranked according to the 2002 TNM classification system using 
the American Joint Committee on Cancer (AJCC) stage grouping1. (Paper I, II, III, IV)  
The T-staging was performed using the histopathology reports. All tumors were 
assigned a pT stage. The clinical lymph node staging was performed based on 
preoperative CT images of the abdomen and/or the preoperative findings. In cases 
with enlarged or palpable lymph nodes between the aorta and vena cava or other 
sites, additional lymph node dissection was performed. Extensive radical 
retroperitoneal lymph node dissection was not conducted. Only 14 of the surgical 
specimens had a sufficient number of negative nodes (eight) to be classified as pN0 
category. Accordingly 161 of the patients were pNx (clinically N0) (Paper III).  
The M-status was preoperatively evaluated by a chest X-ray and kidney/abdominal 
ultrasound scan, which were done in all patients. CT of the abdomen was performed 
in 150 patients (77%). CT scans of the thorax and brain, bone scans, angiography 
and cavography were done selectively when clinically indicated.   
In our study (Paper I) two pathologists (C.G., T.S.) examined every slide and 
performed the nuclear grading, which was done according to Fuhrman.15 The grading 
was determined via consensus. We also investigated the prognostic relevance of 
changing the Fuhrman four-grade system into a two- grade system; low grade 
[Fuhrman nuclear grade (NG) 1 and 2] and high grade [Fuhrman NG 3 and 4]. 
 (Paper I, II, III, IV) 
Histological tumor subtype was diagnosed according to the Heidelberg classification 
guidelines by an experienced nephropathologist (L. B.). (Paper I, II, III, IV) 
The presence of HTN was recorded (L. B.). (Paper I) 
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Performance status was scored by one of the authors (D. P. Z.) from clinical records 
according to the Eastern Cooperative Oncology Group performance status 
classification in all patients. Most of the patients in this series had performance status 
0 and 1 (93.4%) and only a few (6.6%) had performance status 2, which is in line with 
recommendations originating from SWOG and EORTC randomized trials. 18, 19 
(Paper I, III) 
 
6.3.2    Microvascular and vein invasion 
Microvascular invasion was diagnosed only when tumor cell aggregates were seen 
within lumina covered with CD31 positive cells, or when tumor cells penetrated a 
vessel wall. Both sinusoidal and muscular vessels within and close to the tumor were 
assessed. (Paper II) 
Venous invasion was registered as no venous invasion (pV0), renal vein invasion 
(RVI) (pV1) or vena cava invasion (VCI) (pV2) and dichotomized (pV0 vs. pV1+pV2) 
in all except descriptive analyses for compatibility with most previous reports. RVI 
was diagnosed when there was invasion by tumor of major extra renal veins found 
microscopically in transverse slices of the vein. In patients with VCI, the tumor 
thrombus did not adhere to the intima of the vena cava. (Paper III) 
 
6.3.3   Immunohistochemistry and computer assisted morphometry 
The immunohistochemical staining was performed on formalin-fixed, paraffin-
embedded archival tissues (4 µm sections), and conditions were optimized for each 
antibody; TSP-1, p53, Ki-67, Factor VIII and CD31. The DAKO inmmunostainer 
(TechMATE 500) was used. (Paper II, IV) 
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The proliferation index (PI) was scored. At least 1000 tumor cells in 5 different fields 
of view were examined under x400 magnification. Ki-67 expression was 
dichotomized at the value 10%. (Paper IV) 
Microscopic screening of the Factor VIII stained slides by low-power fields (10x 
objective, Olympus BX51 microscope) identified tumor areas with the highest 
microvessel density (hot spots). The average MVD values were calculated in five hot 
spot areas including the tumor rim and the tumor core. (Paper IV) 
A computer assisted morphometric method [AnalySIS Image Processing -Microsoft 
Windows NT5.0 (Build 21915) Service Pack 4] was applied. Screening for hot spots 
in the intratumoral or immediate peritumoral areas revealed the areas with the 
highest staining intensity for TSP-1 under low power magnification (100x) (Olympus 
BX51 microscope). Ten representative images at x400 magnification in hot spot 
areas were taken by microscopic camera (Olympus U-Tvo.5xc). All 
immunohistochemical analyses were completed without knowledge of the clinical 
outcome by (D. P. Z.) supervised by (L. B.) (Paper II, IV) 
 
6.3.4     Statistical analyses 
Preliminary analyses included descriptive statistics and assessment of associations 
by cross tabulations, with exact chi square, linear by linear association or Mann-
Whitney tests. Univariate and multivariate Cox analyses were performed for overall 
survival (Paper I) and cancer specific survival (Paper I, II, III, IV). 
 Kaplan-Meier analysis using the log rank-test was performed for overall survival and 
cancer-specific survival (Paper I), and cancer-specific survival (Paper II, III)  
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Harrell’s concordance indexes (c-indexes)132 with 95% bootstrap BCa confidence 
intervals based on 10 000 bootstrap replications were computed for estimation and 
comparison of predictive ability (PA) of uni- and multivariate Cox models. (Paper I)   
The reproducibility and interobserver agreement between the two pathologists 
independently assessing MVI were measured using Cohen’s kappa. (Paper II)  
All statistical analyses were conducted using SPSS 11.0.1 (Paper I); SPSS 14.0 
(Paper II, III); SPSS 15 (Paper IV) (SPSS Inc., Chicago, IL) and R (The R 
Foundation for Statistical Computing, Vienna, Austria) software. 
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7. Summary of the results 
 
 
7.1   Paper I 
Performance status, tumor stage, nuclear grade and histological tumor necrosis were found 
to be independent predictors for CSS in patients with RCC. 
In this paper we analyzed the prognostic importance of tumor stage, nuclear grade, 
histological subtype, ECOG PS and histological tissue necrosis in a complete cohort 
of 196 patients treated with RN for RCC during 1985-1994. 
By post-hoc multivariate comparisons we found a significant prognostic difference 
among all stages except for stages II and III. The same differences are shown in 
Kaplan-Meier analysis (Figure 9).  
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Figure  9.  Kaplan-Meier survival curves for 196 patients after RN for RCC  
 
No significant difference in CSS was found between patients with NG1 and 2 and 
those with NG3 and 4 tumors (Figure 10).  
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Figure  10.  CSS after RN in 196 patients operated on for RCC as a function of NG. 
 
HTN was found in 26.5% of the tumors and was shown to be an independent 
predictor of CSS for CCRCC (p<0.01), but not for papillary and chromophobe type. 
The clinical ECOG PS (two categories: 0 vs. >0) was found to be a reliable 
prognostic predictor for RCC in both univariate and multivariate analysis.    
 
7.2   Paper II 
Microvascular invasion turned out to be a strong independent predictor for CSS in patients 
with organ-confined CCRCC.  
Of 196 patients, a total of 52 patients with AJCC stage IV and 53 with stage III were 
excluded. After removing 12 patients with papillary and 3 with chromophobe 
carcinoma, the study group consisted of 76 patients with organ-confined CCRCC. 
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MVI was diagnosed only when tumor cell aggregates were seen within lumina 
covered with CD31 positive cells (Figure 11a) or when tumor cells penetrated a 
vessel wall (Figure 11b). Both sinusoidal and muscular vessels within and close to 
the tumor were assessed.  Using these criteria the interobserver agreement was very 
highly significant, bordering on almost perfect (Cohens kappa 0.75). MVI turned out 
to be a strong independent predictor of CSS (Figure 12).                                                                                  
                                                                                                      
 
Figure. 11   Microvascular tumor x 40 obj.). Arrows point at clusters of tumor cells in two sinusoidal   
                 vessels.   (a) Tumor penetrating a vessel wall (arrow) (b).                                                                                            
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Figure 12.  CSS after RN in 76 patients TNM stage pT1 and pT2 CCRCC related to MVI 
                                                                                                              
By Cox multivariate analysis, tumor size coded as continuous variable, showed HR of 
1.2 per cm. Patients with high-grade tumors had an estimated 5-fold higher risk of 
dying of CCRCC compared to patients with low-grade tumors. 
 
7.3   Paper III 
 
In multivariate analysis of interactions of SDM, VI and LNI on survival, LNI showed a 
significant impact on survival only for the patients in whom we found no distant metastases 
or venous invasion.  
A complete cohort of 196 patients treated with RN for RCC was enrolled in this study. 
In multivariate Cox regression analysis only LNI, SDM, VI, and ESR remained 
independent prognostic factors. In patients without LNI we were able to define 
prognostic subgroups of patients based on multivariate analysis by including different 
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combinations of SMD and VI. The same relationships were observed in Kaplan-Meier 
analysis by combinations of LNI, SDM and VI (Figure 13). 
 
 
Figure  13.  Kaplan-Meier analysis of CSS in 175 lymph node negative renal cell carcinoma patients by different 
combinations of synchronous distant metastases (SDM) and venous invasion (VI) and in 21 patients with lymph 
node positive renal cell carcinoma. 
 
7.4      Paper IV 
 
TSP-1 expression was found to be significantly associated with prognostic tumor features 
and was an independent prognostic factor for CSS.  
 
A total of 172 consecutive patients with CCRCC treated with radical nephrectomy 
were initially enrolled in the study. Due to technical reasons and lack of material, 12 
patients could not be tested for TSP-1 expression and were excluded. 
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TSP-1 expression (Figure 14a), p53 status (Figure 14 b), Ki-67 PI (Figure 14 c), MVD 
(Figure 14d), NG and tumor stage were significant prognosticators for CSS. 
Multivariate analysis revealed that TSP-1, tumor stage (P=0.003), p53 status 
(P=0.002), Ki-67 PI (P=0.010) and MVD (P=0.025) were independently significant 
predictive factors for CSS. Our findings reveal a significant inverse correlation 
between p53 status and TSP-1 expression in CCRCC. 
     
 
 
   
 
 
 
 
 
 
 
Figure  14.  (a) Intratumoral intercellular TSP-1 staining (arrows) (x 40 obj.);  (b) p53 staining; (c) Proliferation 
marker (Ki-67) staining; (d) Intratumoral  micro vessel density  (arrows) (Factor VIII staining x 20 obj. 868.9m  x 
656.6 m) 
 
b) a) 
c) d) 
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8. GENERAL DISCUSSION 
 
 
8. Patients and methods 
 
This study is one of the longest follow up studies on RCC conducted so far. It is 
based on a well defined population of more than 280 000 individuals, and includes all 
consecutive patients with RCC treated with RN during a 10 years period at five clinics 
in Värmland County, Sweden. 
Although the total number of patients in the study is small, it consists of a complete 
cohort of RCC cases since very few patients were referred out of the region for 
operation. The limitation of the study is the retrospective view. The strength of the 
study is its long-term follow-up and the high quality of follow-up data that were 
obtained from institutions providing health service, local GPs or population registers. 
 
8.2    Tumor classification and histology (Papers I-IV) 
8.2.1    Tumor stage 
Tumor stage has traditionally been considered the most useful tool in prognostication 
of RCC. Historically, RCC has been staged according to anatomical staging systems 
such as the TNM classification system. Tumor staging  was done according to the 
2002 TNM classification system of the AJCC stage grouping.48 Stage pT1 has been 
subclassified in pT1a and pT1b in order to improve the precision of prognostication in 
this group of patients. In our study (Paper I) we found a significant CSS difference 
between these two substages in line with several other studies.49 133-135 The critical 
cut-off point of 7 cm for organ confined tumors, as recommended by the TNM 
classification, correlated significantly with survival in our population-based study. This 
result is in agreement with some previous reports.55 136 However, it has not been 
 39 
confirmed in a number of other studies.38 51 54 137-138 A possible explanation for this 
divergence might be differences in follow-up periods and inconsistencies in the 
studied populations. Test analysis of our data with a follow-up period of more than10 
years revealed no difference in CSS between pT1 and pT2 tumors, supporting our 
hypothesis that a long follow-up period is of critical importance in analyzing 
prognostic factors for organ-confined RCC. Our results are consistent with Frank’s 
report where a cut-off point at 10 cm is suggested for subclassifying patients in stage 
pT2 into pT2a and pT2b.  
 
8.2.2    Nuclear grade 
Fuhrman’s nuclear four-grade system is the most widely used but its reproducibility 
and prognostic significance has been questioned.9 39 42 45 139-140 Both how to grade 
and the prognostic relevance of the four grades remain matters of debate.43-45 In our 
study the prognostic cut-off lies between grade 2 and 3 (Papers I-IV). Thus, patients 
with low NG tumors had a significantly improved CSS compared with high grade 
tumor patients. This is in accordance with a number of earlier reports.7 23 43 45 141-143 
Our findings support the recommendations given by Bretheau et al.45 to reduce the 
number of grades in order to increase the prognostic significance of grading. This 2-
tiered Fuhrman classification reduces the degrees of freedom and improves the 
efficiency of statistical analyses.144 
The data in the current analysis suggest that NG can be used to predict survival for 
patients with non-metastatic tumors. It follows that high NG may reflect a profound 
change in biological behavior of the tumor when the size of tumor mass has reached 
a critical point.78 A significant survival difference between low and high grade tumors 
was revealed for TNM stage II, which is consistent with Minervini's report.142 
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However, Lang et al.141 and Zisman et al.32 in their studies concluded that the original 
Fuhrman grading system possesses significant independent prognostic value and 
collapsing the system leads to a loss of information.  
 
8.2.3    Histological tumor necrosis  
There are studies concluding that HTN may be an informative prognostic factor in 
RCC.34 39 42 98 145-148 It has even been included in recommended guidelines.149 In 
agreement with this we found HTN to be associated with an increased risk of death 
from RCC that even persisted after multivariate adjustment for ECOG PC, TNM 
stage, tumor size and NG (hazard ratio 1.75; 95% C.I. 1.09 – 2.80; p<0.05) (Paper I). 
While Klatte et al.150 and Isbarn et al.151 previously confirmed that HTN is an adverse 
predictor of survival in CCRCC, they did not find it to have independent statistical 
significance. The possible reasons for the discrepancies reported could be different 
methods of assessment of necrosis, different histological RCC subtypes of the 
populations studied, and absence of a uniform definition of necrosis. Consistent with 
other studies.34 38 145 we found the presence of tumor necrosis in papillary RCC to be 
of little prognostic significance.  
 
8.3   Immunohistochemical methods and use of partly  
         computerized morphometry  
8.3.1   Immunohistochemistry 
Immunohistochemistry was performed using the automated TechMATE system 
(DAKO, Carpentaria, CA, USA).  The sections (4 µm) from the formalin-fixed, 
paraffin-embedded archival tissues were first deparaffinized and then hydrated 
through graded alcohols and water. Antigen retrieval was achieved by microwaving 
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the slides in the retrieval buffer for 10 minutes to boiling point, followed by heating in 
retrieval buffer. Peroxidase was blocked for 5 minutes; slides were then incubated 
with the primary antibodies (Table 1).  Detection was performed using the Envision-
HRP kit (DAKO K4061).  Hematoxylin was used as a counter stain.  Appropriate 
negative and positive controls were used (Papers II, IV). 
 
8.3.2   Partly computerized morphometry 
A computer assisted morphometric method [AnalySIS Image Processing -Microsoft 
Windows NT5.0 (Build 21915) Service Pack 4] was applied.  Prominent hyalinized, 
necrotic, and hemorrhagic areas were excluded from the analysis. As recommended 
by Grossfeld et al.152 the areas examined were chosen based on extracellular 
reactivity for TSP-1. Screening for hot spots in the intratumoral or immediate 
peritumoral areas revealed areas with the highest staining intensity for TSP-1 under 
low power magnification (100x) (Olympus BX51 microscope).  Ten representative 
images at x400 magnification in hot spot areas were taken by microscope mounted 
camera (Olympus U-Tvo.5xc).  All positively stained tumor stroma areas were 
identified and the mean value of area (m2) was computed as a percentage of the 
surface area in the image.  The average area value for each tumor was calculated 
from ten hot spot areas.  The staining intensity level was defined and classified as: 
no = 0, low = 1, moderate = 2, and high level = 3.  The intensity levels were defined 
as phase fractions by setting a color threshold (cut off value) manually for each level 
and were quantified by computing their percentage of the representatively stained 
surface area in the image.  The mean value for each phase fraction (intensity level) in 
ten images (HPF; x400) was calculated.  The highest value determined the staining 
intensity level of the tumor.  Tumor sections were classified as having low TSP-1 
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expression when they showed no or negligible/equivocal reactivity (score 0-1).  
Tumors with detectable TSP-1 immunoreactivity were considered to have moderate 
or high TSP-1 expression (score 2-3).  TSP-1 expression was dichotomized into 
none to low vs. moderate to high (Paper IV). 
 
8.4   Comments on main results 
8.4.1    Clinical presentation and performance status  
The proportion of incidentally detected RCC in the present study is similar to 
contemporary series.14, 15 
The ECOG PS is a recognized predictor for survival in patients with RCC. Most of the 
patients in this series had performance status 0 and 1 (93.4%) and only few had 
performance status 2 (6.6%) which is in line with recommendations originating from 
SWOG and EORTC randomized trials.153-154  ECOG PS was shown to be an 
independent predictor of survival in our patients with RCC which is in accordance 
with other studes.35 155  In a number of studies however, its prognostic power has not 
been confirmed.34 42 
(Papers I and III) 
 
8.4.2   Microvascular invasion 
The frequency of MVI found in our study is comparable with some of those reported 
previously.103-104 156-157  There is, however, a considerable variation in reported 
frequencies of MVI. These discrepancies may be due to different staining methods, 
tissue sampling (the number of tissue slides), interobserver variability, different 
inclusion criteria for tumor thrombus/embolus, and differences in study populations.  
In the study of Sevinç et al., which was limited by the small population studied, CSS 
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was not found to be significantly related to MVI.103  In our study (Paper II) however, 
MVI turned out to be a strong independent prognosticator for organ -confined 
CCRCC after RN, a finding in accordance with most of the previous reports on this 
issue. 99 104 106-107 156 Our patients with MVI positive tumors experienced a nearly 7-
fold higher risk of dying from CCRCC compared with patients in whom the tumor did 
not invade the microvasculature. To our best knowledge there are no other published 
studies reporting on the extent of interobserver agreement between two pathologists 
independently assessing MVI in RCC (Paper II). We established criteria on MVI 
which were strictly followed by the two pathologists. The interobserver agreement 
was substantial, on the borderline to almost perfect (Cohen's kappa: 0.75). 
Contrary to the findings of Lang et al.101 102 when analyzing the MVI data in patients 
followed up shorter than 10 years and even shorter than 5 years, we found that MVI 
had a significant independent impact on CSS (p<0.01).  
 
8.4.3   Interactions of SDM, VI and LNI  
Our data showed a significant interaction between LNI and SDM (p=0.008). SDM 
turned out to be an independent prognostic marker and had the strongest impact 
without simultaneous LNI. However, in some other studies158-159 distant metastatic 
disease did not significantly alter the prognosis in patients with N0VI+ disease.    
Lymph node invasion has been shown to convey a sinister prognosis for RCC 
patients.158-162 The reported incidence of LNI among patients treated with radical 
nephrectomy and lymph node dissection varies from 2% to 14.2%162-164 depending 
on the study population and the time period. In our series (Paper III), 21 patients 
(10.7%) had lymph node metastases. The relatively high incidence of positive nodes 
reflects the patient selection as 45 patients had distant metastases when undergoing 
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RN. Three quarters of the node positive patients had synchronous distant 
metastases, in line with the findings of an autopsy study.165 
Only few studies have analyzed survival by comparing N1/N2M1 and N0M1 disease; 
most patients with M1 disease are grouped together regardless of lymph node status. 
In the absence of LNI however, we found that patients with both SDM and VI had a 
significantly (p=0.012) shorter survival compared with those who had SDM only. The 
CSS difference between these two groups was not observed if LNI was present. In 
accordance with other reports, the impact of VI on survival was highest for patients 
free from nodal and distant metastases, and was insignificant in patients with both 
LNI and SDM.160-161 166  
 
Our findings underline the prognostic importance of the status of the lymph nodes in 
metastatic RCC. A recently published study64 on RCC in patients treated with 
cytoreductive nephrectomy supports our findings.  
In the multivariate analysis of interactions of SDM, VI and LNI on survival, LNI 
showed a significant impact on survival only for the patients in whom we found no 
distant metastases or venous invasion. This finding is also in accordance with a 
recently published large multi-institutional European study63  which showed that 
presence of nodal metastases in non-metastatic RCC had the strongest impact on 
cancer specific mortality of patients with T1 RCC, and intermediate effect for patients 
with T2-T3 RCC. 
 These findings imply that once RCC has spread to the lymphatic system the risk of 
hematogenous spread to other regions is high and it is likely that few patients would 
benefit from extensive lymph node dissection.  
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8.4.4 Thrombospondin-1 and p53 
Both a promotive and an inhibitory role for TSP-1 in cancer cell proliferation and 
metastasis have been suggested.79 167 Our study (Paper IV), however, demonstrated 
that TSP-1 expression was significantly associated with prognostic tumor features.  
We found a significant correlation between p53 status and TSP-1 expression that to 
our knowledge has not been reported previously. Interestingly, a relatively high 
percent (53 %) of the tumors was p53 positive which might imply upregulation of wild 
type protein in some cases. This is supported by the report of Chemeris et al168 which 
demonstrated an adverse impact on prognosis in CCRCC of  upregulation of the wild 
type p53 protein. Post-translational changes of the wild type p53 protein might 
account for the non-functionality of the protein. In multivariate analyses TSP-1 was 
an independent prognosticator of CSS. Absent or low expression of TSP-1 conveyed 
a 5.85 hazard rate of dying from CCRCC compared with moderate or high TSP-1. In 
accordance with our results Arai et al169 reported frequent hypermethylation of the 
CpG island of the TSP-1 gene in CCRCC associated with adverse prognosis. 
In our study TSP-1 and MVD were inversely associated, and high expression was 
detected in areas with stroma fibrosis and in the tumor pseudo capsule. The hot 
spots of MVD and TSP-1 were selected independently. It would be of interest to see 
whether high TSP-1 activity corresponded with low MVD in the same areas. We 
postulate such association which opens up for further investigations on the 
relationship between TSP-1, angiogenesis and fibrosis. 
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 The inhibitory impact of TSP-1 on angiogenesis observed in CCRCC will most likely 
be utilized therapeutically. In fact, a peptide analogue of an angiogenic sequence of 
TSP-1 has shown some effect on survival in phase 1 and 2 trials of untreated 
metastatic RCC. The development of new agents that mimic the antiangiogenic 
properties of TSP-1 warrants further clinical investigations.  
 
 
8.4.5     Proliferation index and TSP-1 expression  
 A high PI (Ki-67) was found in 34% of the tumors in our study (Paper IV), which is in 
accordance with the frequencies reported in previous studies. The PI was 
significantly associated with p53 expression, which is in agreement with the results of 
Kankuri et al. and Zigeuner et al.72 170  Our findings  demonstrate a high proliferation 
index is significantly associated with no/low TSP-1 expression, confirming the results 
of Ren et al. and Miyanaga et al.79 171 Therefore, the TSP-1 protein may have a direct 
effect on the proliferation of tumor cells.  Like Kramer et al. and Kankuri et al.71 72 we 
found the PI to be a significant predictor of CSS in univariate analysis.  However, in 
contrast to the findings of Kramer et al.71 we were able to prove an independent 
significance of this prognosticator in multivariate analyses, which exhibited a high HR 
of 2.37 (p=0.010).   
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9.    Conclusions 
 
 
The current thesis consists of four papers addressing different prognostic factors in 
renal cell carcinoma.  
Paper I  
- Performance status, tumor stage, nuclear grade and tumor necrosis 
were found to be independent prognostic factors for survival in patients 
with RCC.  
- Our findings support the use of a two-grade system to discriminate 
between low- (Fuhrman NG1 and 2) and high-grade (Fuhrman NG 3 and 
4) tumors.  
 Paper II  
- Both tumor size and nuclear grade showed independent prognostic 
significance together with MVI for patients with organ confined CCRCC.    
- Our findings indicate that it may prove to be of clinical importance to 
include MVI together with nuclear grade and tumor size in the 
histopathology report of organ-confined clear cell renal cell carcinoma. 
Paper III  
- Interactions between LNI, VI and SDM were analyzed in patients with 
CCRCC. LNI provided the strongest prognostic information for patients 
without SDM or VI whereas SDM and VI had strongest impact on 
survival when there was no nodal involvement.  
- These findings imply that once RCC has spread to the lymphatic system 
the risk of haematogenous spread to other regions is high and it is likely 
that few patients would benefit from extensive lymph node dissection.  
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Paper IV  
- A new molecular prognostic factor, TSP-1, was found to be an 
independent prognostic factor for cancer specific survival and 
significantly associated with reduced tumor angiogenesis, proliferation 
and aggressiveness. 
- Our findings reveal a significant correlation between p53 status and 
TSP-1 expression in CCRCC. 
. 
 
 
10.   Future perspectives 
 
 
Tumor grade and stage are well known prognostic indicators for patients with RCC 
while MVI is not as well established. Our findings support the use of a two-graded 
nuclear grading system for CCRCC that potentially could reduce inter- and 
intraobserver inconsistencies and improve the prognostic significance of grading. 
This system of grading should be externally validated in a larger patient series to 
confirm its prognostic significance.  
According to our analyses, the presence of MVI in the tumor appeared to portend a 
significantly worse prognosis for patients with low stage CCRCC. Consequently, 
patients with MVI and otherwise considered to be at low risk for progression, should 
be followed more closely than low risk patients without MVI. However, there is a need 
for caution when assessing our results because wide differences in the number of 
tumors found to have MVI have been reported. Despite the considerable variation in 
reported frequencies of MVI, it does appear to be a promising prognostic marker and 
 49 
our findings justify further larger prospective multicentric studies in order to test its 
prognostic significance in conjunction with established prognostic factors. By 
confirming its reproducibility as a prognostic factor in RCC, MVI might be a valuable 
addition to prognostic models.  
The novel finding that TSP-1 is independently associated with cancer-specific 
survival in a population based cohort of patients with CCRCC should be corroborated 
in a larger prospective study. Interestingly, TSP-1 and MVD were inversely 
associated, and high expression was detected in areas with stroma fibrosis and in 
the tumor pseudo capsule. Therefore it would be of interest to see whether high TSP-
1 activity corresponds with low MVD in the same areas. We postulate such an 
association which opens up for further investigations on the relationship between 
TSP-1, angiogenesis and fibrosis. The inhibitory impact of TSP-1 on angiogenesis 
observed in the current study will most likely be used therapeutically. New 
angiogenesis inhibitors that mimic the angiogenetic properties of TSP-1 warrant 
further clinical investigation. 
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